265 related articles for article (PubMed ID: 27062678)
1. A Step Ahead in Secondary Prevention of Cardiovascular Risk. Consensus Document on Clinical Use of the Polypill.
González-Juanatey JR; Mostaza JM; Lobos JM; Abarca B; Llisterri JL
Rev Esp Cardiol (Engl Ed); 2016 Jun; 69(6):547-50. PubMed ID: 27062678
[No Abstract] [Full Text] [Related]
2. Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study.
Barrios V; Kaskens L; Castellano JM; Cosin-Sales J; Ruiz JE; Zsolt I; Fuster V; Gracia A
Rev Esp Cardiol (Engl Ed); 2017 Jan; 70(1):42-49. PubMed ID: 27474481
[TBL] [Abstract][Full Text] [Related]
3. Update to the Consensus Document on Clinical Use of the Polypill: New Dose Containing Atorvastatin 40 mg.
González-Juanatey JR
Rev Esp Cardiol (Engl Ed); 2018 Jul; 71(7):595-596. PubMed ID: 29752030
[No Abstract] [Full Text] [Related]
4. Polypill Strategy in Secondary Cardiovascular Prevention.
Castellano JM; Pocock SJ; Bhatt DL; Quesada AJ; Owen R; Fernandez-Ortiz A; Sanchez PL; Marin Ortuño F; Vazquez Rodriguez JM; Domingo-Fernández A; Lozano I; Roncaglioni MC; Baviera M; Foresta A; Ojeda-Fernandez L; Colivicchi F; Di Fusco SA; Doehner W; Meyer A; Schiele F; Ecarnot F; Linhart A; Lubanda JC; Barczi G; Merkely B; Ponikowski P; Kasprzak M; Fernandez Alvira JM; Andres V; Bueno H; Collier T; Van de Werf F; Perel P; Rodriguez-Manero M; Alonso Garcia A; Proietti M; Schoos MM; Simon T; Fernandez Ferro J; Lopez N; Beghi E; Bejot Y; Vivas D; Cordero A; Ibañez B; Fuster V;
N Engl J Med; 2022 Sep; 387(11):967-977. PubMed ID: 36018037
[TBL] [Abstract][Full Text] [Related]
5. The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention.
Tamargo J; Castellano JM; Fuster V
Int J Cardiol; 2015 Dec; 201 Suppl 1():S15-22. PubMed ID: 26747390
[TBL] [Abstract][Full Text] [Related]
6. The fixed-dose combination drug for secondary cardiovascular prevention project: improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug. Study design and objectives.
Sanz G; Fuster V; Guzmán L; Guglietta A; Arnáiz JA; Martínez F; Sarria A; Roncaglioni MC; Taubert K
Am Heart J; 2011 Nov; 162(5):811-817.e1. PubMed ID: 22093195
[TBL] [Abstract][Full Text] [Related]
7. Use of the cardiovascular polypill 40mg in secondary cardiovascular prevention.
Marzal D; Rodríguez Padial L; Arnáiz JA; Castro A; Cosín J; Lekuona I; Guijarro C
Clin Investig Arterioscler; 2018; 30(5):240-247. PubMed ID: 30017176
[TBL] [Abstract][Full Text] [Related]
8. Consensus document for the use of the Polypill in the secondary prevention of cardiovascular disease.
González-Juanatey JR; Mostaza JM; Lobos JM; Abarca B; Llisterri JL; Baron-Esquivias G; Galve E; Lidón RM; Garcia-Moll FX; Sánchez PL; Suárez C; Millán J; Pallares V; Alemán JJ; Egocheaga I
Med Clin (Barc); 2017 Feb; 148(3):139.e1-139.e15. PubMed ID: 27993410
[TBL] [Abstract][Full Text] [Related]
9. Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients.
Ros-Castelló V; Natera-Villalba E; Gómez-López A; Sánchez-Sánchez A; Chico-García JL; García-Madrona S; Vera-Lechuga R; Matute-Lozano C; de Felipe Mimbrera A; Cruz-Culebras A; Alonso-Canovas A; Masjuan J
Cerebrovasc Dis Extra; 2020; 10(3):166-173. PubMed ID: 33176324
[TBL] [Abstract][Full Text] [Related]
10. Improving cardiovascular protection: focus on a cardiovascular polypill.
Barrios V; Escobar C
Future Cardiol; 2016 Mar; 12(2):181-96. PubMed ID: 26652213
[TBL] [Abstract][Full Text] [Related]
11. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
; Yusuf S; Pais P; Afzal R; Xavier D; Teo K; Eikelboom J; Sigamani A; Mohan V; Gupta R; Thomas N
Lancet; 2009 Apr; 373(9672):1341-51. PubMed ID: 19339045
[TBL] [Abstract][Full Text] [Related]
12. ACE inhibitor reduces cardiovascular events by 22%.
Indian J Med Sci; 2000 Mar; 54(3):112-4. PubMed ID: 11227615
[No Abstract] [Full Text] [Related]
13. The HOPE study: comparison with other trials of secondary prevention.
Otterstad JE; Sleight P
Eur Heart J; 2001 Aug; 22(15):1307-10. PubMed ID: 11465962
[No Abstract] [Full Text] [Related]
14. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe.
Thom S; Field J; Poulter N; Patel A; Prabhakaran D; Stanton A; Grobbee DE; Bots ML; Reddy KS; Cidambi R; Rodgers A
Eur J Prev Cardiol; 2014 Feb; 21(2):252-61. PubMed ID: 23038750
[TBL] [Abstract][Full Text] [Related]
15. Do the current medical and economic times dictate the need for the "polypill"?
Rifai L; Khan BV
J Clin Hypertens (Greenwich); 2009 Dec; 11(12):775-6. PubMed ID: 20021541
[No Abstract] [Full Text] [Related]
16. A new horizon in primary prevention of cardiovascular disease, can we prevent heart attack by "heart polypill"?
Rastegarpanah M; Malekzadeh F; Thomas GN; Mohagheghi A; Cheng KK; Marshall T
Arch Iran Med; 2008 May; 11(3):306-13. PubMed ID: 18426322
[No Abstract] [Full Text] [Related]
17. Drug therapies in the secondary prevention of cardiovascular diseases: Successes, shortcomings and future directions.
Lonn E; Grewal J
Curr Vasc Pharmacol; 2006 Jul; 4(3):253-68. PubMed ID: 16842143
[TBL] [Abstract][Full Text] [Related]
18. The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study.
Xavier D; Pais P; Sigamani A; Pogue J; Afzal R; Yusuf S;
Nat Clin Pract Cardiovasc Med; 2009 Feb; 6(2):96-7. PubMed ID: 19104516
[No Abstract] [Full Text] [Related]
19. Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States.
Gaziano TA; Pandya A; Sy S; Jardim TV; Ogden JM; Rodgers A; Weinstein MC
Am Heart J; 2019 Aug; 214():77-87. PubMed ID: 31174054
[TBL] [Abstract][Full Text] [Related]
20. Polypill: Can its Potential Enhancement of Efficacy Trigger New Interest?
Chao J; Bansilal S
Glob Heart; 2016 Dec; 11(4):469-472. PubMed ID: 27938845
[No Abstract] [Full Text] [Related]
[Next] [New Search]
